rel-Methyl (2R,3S)-3-((tert-butoxycarbonyl)amino)piperidine-2-carboxylate

Catalog No. :
ACOBRA548
CAS No. :
2055248-91-2
Molecular Formula :
C24H44N4O8
Molecular Weight :
516.64

IUPAC Name:rel-Methyl (2R,3S)-3-((tert-butoxycarbonyl)amino)piperidine-2-carboxylate

rel-Methyl (2R,3S)-3-((tert-butoxycarbonyl)amino)piperidine-2-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$445.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Namerel-Methyl (2R,3S)-3-((tert-butoxycarbonyl)amino)piperidine-2-carboxylate
IUPAC Namerel-Methyl (2R,3S)-3-((tert-butoxycarbonyl)amino)piperidine-2-carboxylate
Molecular FormulaC24H44N4O8
Molecular Weight516.64
SMILESCOC(=O)[C@@H]1NCCC[C@@H]1NC(=O)OC(C)(C)C.COC(=O)[C@H]1NCCC[C@H]1NC(=O)OC(C)(C)C
InChI KeyQZIAPYJDXPTNGY-QUOODJBBSA-N
Synonymrel-Methyl (2R,3S)-3-((tert-butoxycarbonyl)amino)piperidine-2-carboxylate;rac-methyl (2R,3S)-3-{[(tert-butoxy)carbonyl]amino}piperidin e-2-carboxylate;2-Piperidinecarboxylic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-, methyl ester, (2R,3S)-rel-
CAS No.2055248-91-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACOBRA548 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRTMN327 route compound structure diagram
    ACRTMN327912369-42-7 In Stock
  2. Then
  3. ACOBRA548 route product structure diagram
    ACOBRA5482055248-91-2
Inquiry

2. ACOBRA548 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACOBRA548 route product structure diagram
    ACOBRA5482055248-91-2
Inquiry

Comments (0)